Gefitinib in Recurrent Non–Small-Cell Lung Cancer: An IDEAL Trial?
- 15 June 2003
- journal article
- editorial
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 21 (12) , 2227-2229
- https://doi.org/10.1200/jco.2003.04.001
Abstract
No abstract availableThis publication has 21 references indexed in Scilit:
- Multi-Institutional Randomized Phase II Trial of Gefitinib for Previously Treated Patients With Advanced Non–Small-Cell Lung CancerJournal of Clinical Oncology, 2003
- Influence of Unrecognized Molecular Heterogeneity on Randomized Clinical TrialsJournal of Clinical Oncology, 2002
- Women who smoke: are women more susceptible to tobacco-induced lung cancer?Carcinogenesis: Integrative Cancer Research, 2002
- Efficacy and Safety of Trastuzumab as a Single Agent in First-Line Treatment of HER2-Overexpressing Metastatic Breast CancerJournal of Clinical Oncology, 2002
- Women and lung cancer: does oestrogen play a role?Published by Elsevier ,2001
- Use of Chemotherapy plus a Monoclonal Antibody against HER2 for Metastatic Breast Cancer That Overexpresses HER2New England Journal of Medicine, 2001
- Employment of the Epidermal Growth Factor Receptor in Growth Factor–Independent Signaling PathwaysThe Journal of cell biology, 1999
- Up-Regulation by Progesterone of Proliferating Cell Nuclear Antigen and Epidermal Growth Factor Expression in Human Uterine LeiomyomaJournal of Clinical Endocrinology & Metabolism, 1998
- Epidermal growth factor receptor (EGFr) expression in non-small cell lung carcinomas correlates with metastatic involvement of hilar and mediastinal lymph nodes in the squamous subtypeEuropean Journal Of Cancer, 1995
- K-rasOncogene Activation as a Prognostic Marker in Adenocarcinoma of the LungNew England Journal of Medicine, 1990